《急性心肌梗死的紧急干预》课件.ppt

Acute Myocardial Infarction (AMI): The Urgent Intervention;AMI Disease State;AMI Disease State;AMI Disease State;AMI Disease State;AMI Disease State;AMI Diagnosis;Abciximab Indication;Clinical Studies of AMI and Abciximab;PCI with Abciximab for AMI;Abciximab Administration;PCI;Abciximab and PCI;RAPPORT Study;RAPPORT: Trial Design;RAPPORT: 6-Month ITT Outcome;Placebo (n=242);0;Abciximab (n=241);RAPPORT: Conclusions;Neumann Study;Neumann Trial Design ;Cardiac Function Parameters at 14 days;Usual care (n=72);Neumann: Conclusions;ISAR-2 Study;ISAR-2: Trial Design;ISAR-2: 6-Month Late Loss;Usual Care (n=200);ISAR-2: 1-Year Event-Free Survival;ISAR-2: 30-Day Safety Data;ISAR-2: Conclusions;ADMIRAL Study;ADMIRAL: Trial Design;ADMIRAL: Inclusion Criteria;ADMIRAL: 30-Day Clinical Events;;ADMIRAL: 6-Month Clinical Events;0;ADMIRAL: Early Abciximab Administration;ADMIRAL: LVEF;ADMIRAL: 30-Day Safety Data;ADMIRAL: Conclusions;CADILLAC Study;CADILLAC: Overall Study Design;CADILLAC: Addressing the Abciximab Question;CADILLAC: 30-Day Outcomes;CADILLAC: 30-Day Subacute Thrombosis;CADILLAC: 1-Year Outcomes;CADILLAC: 30-Day Safety Data;CADILLAC: Conclusions;ACE Study;ACE: Trial Design;;;ACE: 30-Day Sestamibi Results;;;ACE: Conclusions;2004 ACC/AHA STEMI Guidelines;Conclusions;Safety Information;Bleeding Risk;Non-CABG Bleeding in Trials of Percutaneous Coronary Intervention (EPILOG and EPISTENT);Guidelines for Reduction in Bleeding;Thrombocytopenia;Dosage and Administration;Onset and Reversibility;Readministration of Abciximab ;Readministration of Abciximab (Cont.) ;Contraindications;Contraindications (Cont.)